One of the challenges in treating hemophilia is that patients frequently develop antibodies to the protein(s) used to correct clotting factor deficiencies. This patented technology is a method for oral administration of a clotting factor to induce immunologic tolerance while providing therapeutic levels of clotting factor replacement. The method can be a stand-alone treatment, or can be used in combination with other treatments.